Skip to main content

God's Will Changes (in Shariah Finance)

Image result for God

This is big news, both in the world of finance and in that of, well  ... Islamic theology.

In May of this year, [I'm sorry I'm late to this table] a company headquartered in the United Arab Emirates, Dana Gas, declared that $700 million of its sukuk bonds were, simply, invalid. It obtained a preliminary injunction against creditor enforcement. That may have been an opening negotiation ploy in a sense -- Dana coupled this announcement with an exchange offer, proposing to give its creditors new bonds for the old, with a haircut of more than half the value of the old.

Jason Kilborn calls this an "existential crisis" for the whole field of Islamic finance, or Shariah-compliant finance, of which these bonds were an example.

Does Dana Gas propose to change the rules -- rules that supposedly represent God's will, by its own sayso?

Well, no. Not exactly. But kinda.

Here is Kilborn's take: http://www.creditslips.org/creditslips/2017/06/dana-gas-and-an-existential-crisis-for-islamic-finance.html

Here's a Reuters story:  http://www.reuters.com/article/dana-gas-sukuk-idUSL8N1JB05A 

Islamic law prohibits lending money for interest or, what is the same, buying (conventional) bonds. Nonetheless, there are lots of "sukuk" bonds circulating in the world, that is, bonds that are marketed as Shariah compliant, using various structures approved by boards of experts in which that prohibition does and doesn't mean.

One of the structures behind sukuk issuance -- indeed, a very familiar one in the field -- is known as mudarabah. This means that a partnership interest lies beneath the issuance. The idea is that a loan isn't really a loan if one partner issues an IOU to another -- its incidental to the equity interest.

A somewhat different way of accepting a non-loan loan, that is, selling approved sukuk, is known as ijarah. If the sukuk is ijarah, then some asset has changed hands, and the quasi-interest payments are lawfully considered payments on the lease of that asset.

I'm sorry if your eyes are glazing over. But here is the audacity of what Dana Gas is pulling. They claim that the sukuk they issued in 2013 under a partnership agreement were invalid, in violation of Shariah, because ijarah has supplanted mudaradah in the development of Shariah finance. They were apparently behind that curve at time of issuance, and they regret it now, but  ... whatcha gonna do?

This is blatantly wrong. The two structures (and several others) have long been considered alternative ways of doing the same thing (laundering interest payments, to be blunt about it). Neither has supplanted the other in any sense but the imagination of Dana's advisors.

The bondholders seem determined to fight this in the courts of the region. Thus far (into the month of July) the issuer hasn't even been able to get the bondholders to return their calls. Literally. They keep trying to arrange a teleconference to discuss new terms of payment, and they have been repeatedly forced to reschedule.

With what tricks dost thou not endow the minds of men, oh accursed hunger for gold?
(Statius wrote that. Or something like that. I think.)

Comments

  1. Quantum Binary Signals

    Professional trading signals delivered to your cell phone every day.

    Start following our signals today & gain up to 270% per day.

    ReplyDelete

Post a Comment

Popular posts from this blog

A Story About Coleridge

This is a quote from a memoir by Dorothy Wordsworth, reflecting on a trip she took with two famous poets, her brother, William Wordsworth, and their similarly gifted companion, Samuel Taylor Coleridge.



We sat upon a bench, placed for the sake of one of these views, whence we looked down upon the waterfall, and over the open country ... A lady and gentleman, more expeditious tourists than ourselves, came to the spot; they left us at the seat, and we found them again at another station above the Falls. Coleridge, who is always good-natured enough to enter into conversation with anybody whom he meets in his way, began to talk with the gentleman, who observed that it was a majestic waterfall. Coleridge was delighted with the accuracy of the epithet, particularly as he had been settling in his own mind the precise meaning of the words grand, majestic, sublime, etc., and had discussed the subject with William at some length the day before. “Yes, sir,” says Coleridge, “it is a majestic wate…

Hume's Cutlery

David Hume is renowned for two pieces of cutlery, the guillotine and the fork.

Hume's guillotine is the sharp cut he makes between "is" statements and "ought" statements, to make the point that the former never ground the latter.

His "fork" is the division between what later came to be called "analytic" and "synthetic" statements, with the ominous observation that any books containing statements that cannot be assigned to one or the other prong should be burnt.

Actually, I should acknowledge that there is some dispute as to how well or poorly the dichotomy Hume outlines really maps onto the analytic/synthetic dichotomy. Some writers maintain that Hume meant something quite different and has been hijacked. Personally, I've never seen the alleged difference however hard they've worked to point it out to me.

The guillotine makes for a more dramatic graphic than a mere fork, hence the bit of clip art above.

I'm curious whe…

Cancer Breakthrough

Hopeful news in recent days about an old and dear desideratum: a cure for cancer. Or at least for a cancer, and a nasty one at that.

The news comes about because investors in GlaxoSmithKline are greedy for profits, and has already inspired a bit of deregulation to boot. 

The FDA has paved the road for a speedy review of a new BCMA drug for multiple myeloma, essentially cancer of the bone marrow. This means that the US govt has removed some of the hurdles that would otherwise (by decision of the same govt) face a company trying to proceed with these trials expeditiously. 

This has been done because the Phase I clinical trial results have been very promising. The report I've seen indicates that details of these results will be shared with the world on Dec. 11 at the annual meeting of the American Society of Hematology. 

The European Medicines Agency has also given priority treatment to the drug in question. 

GSK's website identifies the drug at issue as "GSK2857916," althou…